

Cosentyx (Secukinumab)—J3247

Patient Name	Middle	Last	DOB
--------------	--------	------	-----

Diagnosis	Diagnosis Code
-----------	----------------

Height (cm)	Actual Weight (kg)	Allergies
-------------	--------------------	-----------

Required labs prior to treatment:

- TB screening

Recommended labs prior to treatment:

- CBC(w/diff)/CMP
 - Hepatitis B Serology
 - Hepatitis C Virus Antibody
 - HIV
 - Pregnancy Test
 - C-reactive Protein
-

Please list any premeds needed.

Intravenous Dosing of secukinumab is approved for the following indications:

- Ankylosing spondylitis, Axial Spondyloarthritis, Psoriatic Arthritis
- Please select the appropriate box(es) below
 - Loading Dose: 6 mg/kg Intravenously x 1 dose at week 0.
 - Maintenance Dose: 1.75 mg/kg Intravenously (max dose 300mg) every 4 weeks.

In the event of a hypersensitivity reaction, patients will be treated according to NECS protocols for the management of infusion-room drug reactions.

_____ Provider Name		_____ Provider Signature	
_____ Date	_____ Phone	_____ Fax	_____ Pager